NASDAQ · PLURHealthcareBiotechnology

Pluri financials

$1.01+4.02%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Jun 30
FY25
Jun 30
FY24
Jun 30
FY23
Jun 30
Revenue$1.0M$1.3M$326.0K$287.0K
Gross profit$453.0K$654.0K$322.0K$278.0K
Gross margin44.6%49.0%98.8%96.9%
Operating income-$24.5M-$22.4M-$22.2M-$28.0M
Net income-$23.8M-$22.6M-$20.9M-$28.3M
Net margin−2344.6%−1690.3%−6407.4%−9867.9%
Diluted EPS$-2.44$-3.56$-3.99$-6.24
EBITDA-$24.0M-$22.1M-$21.9M-$27.7M
Operating cash flow-$19.6M-$18.2M-$18.0M-$23.7M
Free cash flow-$20.2M-$19.5M-$18.3M-$23.9M
Diluted shares9.7M6.3M5.2M4.6M

Balance sheet

Period endJun 30Jun 30Jun 30Jun 30
Cash & equivalents$3.5M$5.9M$6.8M$5.4M
Short-term investments$0.00$0.00$0.00$34.8M
Total debt$27.4M$27.3M$24.0M$23.5M
Total assets$24.9M$38.7M$39.5M$50.8M
Total liabilities$40.3M$39.5M$34.1M$35.5M
Shareholders' equity-$15.4M-$865.0K$5.4M$15.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology